Lipella Pharmaceuticals Inc (LIPO) Dividendos

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2022-12-20. The firm is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The firm is addressing two indications via the development of its product candidates, which it has designated as LP-10 for the indication of hemorrhagic cystitis (HC) and LP-310 for the indication of oral lichen planus (OLP), which is chronic, uncontrolled urinary blood loss that results from certain chemotherapies (such as alkylating agents) or pelvic radiation therapy (also called radiation cystitis). In the third program, the Company is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). In a fourth program, the Company is also developing an intravesical formulation of immunoglobulins including checkpoint inhibitors, referred to as LP-50.